These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11899622)

  • 21. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug evaluation: new requirements and perspectives].
    Addis A; Rocchi F
    Recenti Prog Med; 2006 Nov; 97(11):618-25. PubMed ID: 17252718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the reactions used for the preparation of drug candidate molecules.
    Carey JS; Laffan D; Thomson C; Williams MT
    Org Biomol Chem; 2006 Jun; 4(12):2337-47. PubMed ID: 16763676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
    Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
    Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incident reporting in one UK accident and emergency department.
    Tighe CM; Woloshynowych M; Brown R; Wears B; Vincent C
    Accid Emerg Nurs; 2006 Jan; 14(1):27-37. PubMed ID: 16321534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging technologies supporting chemical process R&D and their increasing impact on productivity in the pharmaceutical industry.
    Rubin AE; Tummala S; Both DA; Wang C; Delaney EJ
    Chem Rev; 2006 Jul; 106(7):2794-810. PubMed ID: 16836299
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of a systematic risk analysis method to improve safety in the production of paediatric parenteral nutrition solutions.
    Bonnabry P; Cingria L; Sadeghipour F; Ing H; Fonzo-Christe C; Pfister RE
    Qual Saf Health Care; 2005 Apr; 14(2):93-8. PubMed ID: 15805453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug safety, drug quality, drug analysis.
    Görög S
    J Pharm Biomed Anal; 2008 Sep; 48(2):247-53. PubMed ID: 18082992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Industrial-scale manufacturing of pharmaceutical-grade bioactive peptides.
    Agyei D; Danquah MK
    Biotechnol Adv; 2011; 29(3):272-7. PubMed ID: 21238564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enabling continuous-flow chemistry in microstructured devices for pharmaceutical and fine-chemical production.
    Kockmann N; Gottsponer M; Zimmermann B; Roberge DM
    Chemistry; 2008; 14(25):7470-7. PubMed ID: 18613163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety.
    Coppens P; da Silva MF; Pettman S
    Toxicology; 2006 Apr; 221(1):59-74. PubMed ID: 16469424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
    Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated operation of continuous chromatography and biotransformations for the generic high yield production of fine chemicals.
    Bechtold M; Makart S; Heinemann M; Panke S
    J Biotechnol; 2006 Jun; 124(1):146-62. PubMed ID: 16516996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategic applications of toxicogenomics in early drug discovery.
    Ryan TP; Stevens JL; Thomas CE
    Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Significance of new effective-substances for basic research].
    Kobinger W
    Subsid Med; 1975; 1-2():13-5. PubMed ID: 1114844
    [No Abstract]   [Full Text] [Related]  

  • 36. Critical assessment of pharmaceutical processes--A rationale for changing the synthetic route.
    Butters M; Catterick D; Craig A; Curzons A; Dale D; Gillmore A; Green SP; Marziano I; Sherlock JP; White W
    Chem Rev; 2006 Jul; 106(7):3002-27. PubMed ID: 16836307
    [No Abstract]   [Full Text] [Related]  

  • 37. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety.
    Woo J; Wolfgang S; Batista H
    Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the "greenness" of chemical processes and products in the pharmaceutical industry--a green metrics primer.
    Jiménez-González C; Constable DJ; Ponder CS
    Chem Soc Rev; 2012 Feb; 41(4):1485-98. PubMed ID: 22076593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.